Paper Details

  1. Home
  2. Paper Details

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.

Author: BauerTodd M, FelipEnriqueta, GotoYasushi, IadelucaLaura, KimDong-Wan, LiuGeoffrey, MazieresJulien, MokTony, PolliAnna M, ReismanArlene, ShawAlice T, SolomonBenjamin J, ThurmHolger, de MarinisFilippo

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This abstract presents patient-reported outcome (PRO) data from the CROWN study, which compared lorlatinib with crizotinib in patients with previously untreated ALK-positive advanced non-small cell lung cancer (NSCLC). The study focused on evaluating quality of life (QoL) and its impact on patients with NSCLC, considering the disease and treatment side effects. Detailed PRO data analysis is presented to provide insights into patient experiences and the potential benefits of lorlatinib in terms of QoL compared to crizotinib.
Paper Details　
Original Abstract of the Article :
Quality of life (QoL) for patients with non-small cell lung cancer (NSCLC) is negatively impacted by their disease and treatment side effects. We present detailed patient-reported outcome (PRO) data from the phase 3 CROWN study, which compared lorlatinib with crizotinib in patients with previously u...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2022.11.004

データ提供：米国国立医学図書館（NLM）

Lorlatinib vs. Crizotinib in Advanced ALK-Positive NSCLC: A Quality of Life Perspective

Non-small cell lung cancer (NSCLC) is a challenging disease, and its treatment can impact a patient's quality of life. This research delves into the patient-reported outcomes from the CROWN study, which compared lorlatinib and crizotinib in patients with advanced ALK-positive NSCLC. The study focused on understanding how these treatments affected the quality of life of patients battling this disease. This study is like a journey through the desert of cancer treatment, seeking to find the path that best balances effectiveness and quality of life.

Lorlatinib: A Promising Option for Improving Quality of Life

This research provides valuable information on the patient-reported outcomes associated with lorlatinib and crizotinib. The study found that lorlatinib was associated with improved quality of life compared to crizotinib. This information can help patients and their doctors make informed decisions about treatment options. Just like a traveler chooses the path that offers the best balance of comfort and progress, patients can now make informed choices about their treatment based on quality of life considerations.

Navigating the Landscape of Cancer Treatment

The findings of this study highlight the importance of considering quality of life in cancer treatment. It underscores the need for treatments that not only effectively target the disease but also minimize side effects and preserve overall well-being. It's like finding an oasis of comfort and strength within the harsh landscape of cancer treatment.

Dr.Camel's Conclusion

This research provides valuable insights into the quality of life aspects of cancer treatment. It's a reminder that we must not only seek to cure disease but also to improve the quality of life for our patients. Just as a camel adapts to the harsh desert environment, we must find ways to help patients navigate the challenges of cancer treatment with grace and resilience.

Date :
  1. Date Completed 2022-12-16
  2. Date Revised 2022-12-21
Further Info :

Pubmed ID

36410210

DOI: Digital Object Identifier

10.1016/j.lungcan.2022.11.004

Related Literature

Article Analysis
・Side Effects of lorlatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.